153747-97-8

Basic information

• Product Name: 4-BOC-1-(5-BROMO-2-PYRIDYL)PIPERAZINE
• Synonyms: 4-(5-Bromo-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester;2-(N-Boc-piperazin-1-yl)-5-bromopyridine, tert-Butyl 4-(5μ-bromopyrid-2μ-yl)piperazine-1-carboxylate;5-Bromo-2-[4-(N-Boc)piperazin-1-yl]pyridine;1-Piperazinecarboxylic acid, 4-(5-bromo-2-pyridinyl)-, 1,1-dimethylethyl ester;2-(4-BOC-piperazino)-5-bromopyridine;t-Butyl 4-(5-bromopyridin-2-yl)piperazine-1-carboxylate;Palbociclib impurity C;4-Boc-1-(5-bromo-2-pyridyl)piperazine 97%
• CAS NO: 153747-97-8
• Molecular Formula: C₁₄H₂₀BrN₃O₂
• Molecular Weight: 342.23
• Product Categories: pharmacetical;Organohalides;Pyridine;piperazines;alkyl bromide
• Mol File: 153747-97-8.mol
• Article Data: 19

Chemical Properties

• Melting Point: 83-87 °C(lit.)
• Boiling Point: 433°Cat760mmHg
• Flash Point: 215.6°C
• Appearance: White to yellow/Powder
• Density: 1.372g/cm³
• Vapor Pressure: 1.06E-07mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.06±0.29(Predicted)
• Water Solubility: Soluble in water.
• CAS DataBase Reference: 4-BOC-1-(5-BROMO-2-PYRIDYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BOC-1-(5-BROMO-2-PYRIDYL)PIPERAZINE(153747-97-8)
• EPA Substance Registry System: 4-BOC-1-(5-BROMO-2-PYRIDYL)PIPERAZINE(153747-97-8)

Safety Data

• Hazard Codes: T
• Statements: 25-36/37/38
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• Hazardous Substances Data: 153747-97-8(Hazardous Substances Data)

Usage

Uses

4-Boc-1-(5-bromo-2-pyridyl)piperazine is used as active pharmaceutical ingredient.

InChI:InChI=1/C14H20BrN3O2/c1-14(2,3)20-13(19)18-8-6-17(7-9-18)12-5-4-11(15)10-16-12/h4-5,10H,6-9H2,1-3H3

Upstream product

• 53939-30-3 5-bromo-2-chloropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 624-28-2 2,5-dibromopyridine 
• 149771-44-8 8-t-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octane 
• 766-11-0 5-bromo-2-fluoropyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73406-97-0 5-bromo-2-(piperazin-1-yl)pyridine 

Downstream Products

• 926646-63-1 tert-butyl 4-(5-phenylpyridin-2-yl)piperazine-1-carboxylate 
• 496786-98-2 2-(4-tert-butyloxycarbonyl-piperizin-1-yl)pyridine-5-boronic acid pinacol ester 
• 683274-61-5 tert-butyl 4-(5-cyanopyridine-2-yl)piperazine-1-carboxylate 
• 1188918-41-3 N-({(5S)-3-[3-fluoro-4-(6-{4-[(2-methyl-6-nitro-2,3-dihydro-imidazo[2,1-b][1,3]oxazol-2-yl)methyl]-1-piperazinyl}-3-pyridinyl)-phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide 
• 380381-49-7 N-[((5S)-3-{3-fluoro-4-[6-(1-piperazinyl)-3-pyridinyl]-phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 
• 919347-67-4 (6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridin-3-yl)boronic acid 
• 73406-97-0 5-bromo-2-(piperazin-1-yl)pyridine 

Relevant articles and documents

Selective Amination of Polyhalopyridines Catalyzed by a Palladium-Xantphos Complex

(Matrix presented) Amination of 5-bromo-2-chloropyridine (1a) catalyzed by a palladium-Xantphos complex predominately gives 5-amino-2-chloropyridine product 3a in 96% isolated yield and excellent chemoselectivity (3a/4a = 97:3). Amination of 2,5-dibromopyridine (11) under the same conditions exclusively affords 2-amino-5-bromopyridine 4a.

RET selective inhibitor as well as preparation method and application thereof

The invention provides an RET selective inhibitor as well as a preparation method and application thereof. The present invention provides compounds of formula(I) and pharmaceutically acceptable salts,solvates, polymorphs or isomers thereof, pharmaceutical compositions comprising these compounds, and the use of such compounds in the treatment of RET-related diseases.

CDK9 inhibiting compound and application thereof

The invention discloses a CDK9 inhibiting compound and application thereof, the structural formula of the CDK9 inhibiting compound is shown in the specification, A is alkyl diamine, X is halogen or H, and R is substituted benzyl. The compound can be used as a CDK9 inhibitor for down-regulating cancer cells PD-L1, and is used for tumor immunotherapy and AIDS treatment.